Cytoagents Inc.

Pittsburgh, PA

UEI
CCEZCKNKL9M4
CAGE
8CQA6
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
100 S Commons #102, Pittsburgh, PA 15212, USA
Website
cytoagents.com
Founded
2018
Employees
11-50
Estimated annual revenue
$1M-$10M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

About Cytoagents Inc.

Cytoagents Inc. is a for-profit corporate entity based in Pittsburgh, Pennsylvania, registered in the System for Award Management (SAM) since July 2019. The company focuses on developing pharmaceutical compounds that modulate inflammatory responses, with a particular emphasis on innovative treatments for complex medical conditions. Its primary research appears centered on developing immunomodulatory agents designed to mitigate severe inflammatory responses in various medical contexts.

The company has secured multiple federal grant awards from key research agencies, specifically the National Cancer Institute and the National Institute of Allergy and Infectious Diseases. These grants have supported the preclinical development of compounds like CTO1681 and GP1681, which are designed to address critical medical challenges such as cytokine release syndrome (CRS) in CAR T-cell therapy and inflammatory responses in viral infections like COVID-19. The most recent grant, awarded in September 2025 from the National Cancer Institute, provides $1,313,567 to develop CTO1681, a compound aimed at preventing and treating cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy. Previous grants have focused on developing immunomodulatory agents to regulate inflammatory responses, with a specific project from March 2021 targeting SARS-CoV-2 related hypercytokinemia. These research projects demonstrate Cytoagents' commitment to developing targeted therapeutic interventions that can potentially reduce severe inflammatory complications in complex medical treatments.

Quick answers

What is Cytoagents Inc.'s UEI?

Cytoagents Inc.'s Unique Entity ID (UEI) in SAM.gov is CCEZCKNKL9M4.

What is Cytoagents Inc.'s CAGE code?

Cytoagents Inc.'s CAGE code is 8CQA6.

What is Cytoagents Inc.'s primary NAICS code?

Cytoagents Inc.'s primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).

Where is Cytoagents Inc. located?

Cytoagents Inc.'s physical address in SAM.gov is 100 S Commons #102, Pittsburgh, PA 15212, USA.

Is Cytoagents Inc. registered in SAM.gov?

Yes. Cytoagents Inc.'s SAM.gov registration is active through July 13, 2027.

What is Cytoagents Inc.'s most recent federal award?

Cytoagents Inc.'s most recent federal grant award is CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving car t-cell therapy -… (R44CA295189), from National Cancer Institute, on September 22, 2025.

On GovTribe

See Cytoagents Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors